Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan

Cefazolin is traditionally active against Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) isolates. The Clinical and Laboratory Standards Institute (CLSI) has twice updated cefazolin susceptibility breakpoints for EKP since 2010, but its role in the definitive treatment of cefazoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ching-Chi, Lee, Chung-Hsun, Chen, Po-Lin, Hsieh, Chih-Chia, Tang, Hung-Jen, Ko, Wen-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963614/
https://www.ncbi.nlm.nih.gov/pubmed/31717641
http://dx.doi.org/10.3390/antibiotics8040216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963614/
https://www.ncbi.nlm.nih.gov/pubmed/31717641
http://dx.doi.org/10.3390/antibiotics8040216

Ejemplares similares